# EDGAR Filing Document

**Accession Number:** 0000064803
**File Stem:** 0001193125-25-289805
**Filing Date:** 2025-11
**Character Count:** 8618
**Document Hash:** 0d59ddbf563e9f72bf0ceb0edf9a4910
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-289805.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0001193125-25-289805

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251120

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251120

**DATE AS OF CHANGE**: 20251120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CVS HEALTH Corp
- **CENTRAL INDEX KEY:** 0000064803
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 050494040
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-01011
- **FILM NUMBER:** 251503255

**BUSINESS ADDRESS:**
- **STREET 1:** ONE CVS DR.
- **CITY:** WOONSOCKET
- **STATE:** RI
- **ZIP:** 02895
- **BUSINESS PHONE:** 4017651500

**MAIL ADDRESS:**
- **STREET 1:** ONE CVS DR.
- **CITY:** WOONSOCKET
- **STATE:** RI
- **ZIP:** 02895

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CVS CAREMARK CORP
- **DATE OF NAME CHANGE:** 20070509

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CVS/CAREMARK CORP
- **DATE OF NAME CHANGE:** 20070322

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CVS CORP
- **DATE OF NAME CHANGE:** 19970128

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, DC 20549

### FORM 8-K

#### CURRENT REPORT

#### PURSUANT TO SECTION 13 OR 15(D)

#### OF THE SECURITIES EXCHANGE ACT OF 1934

#### Date of report (Date of earliest event reported): November 20, 2025
![LOGO](g172430g1118230839704.jpg)

## CVS HEALTH CORPORATION

#### (Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-01011** | **05-0494040** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

#### One CVS Drive

#### Woonsocket, Rhode Island 02895

#### (Address of Principal Executive Offices, and Zip Code)
(401) 765-1500

#### Registrant's Telephone Number, Including Area Code

#### N/A

#### (Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, par value $0.01 per share | CVS | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 8.01.** | **Other Events.**  |

---

*Appointment of J. David Joyner as Chair of the Board of Directors* 

On November 20, 2025, the Board of Directors (the "Board") of CVS Health Corporation (the "Company") appointed J. David Joyner, President and Chief Executive Officer of the Company, to the additional role of Chair of the Board, effective January 1, 2026. Following the effective date of this appointment, Michael F. Mahoney will continue to serve as the Board's Lead Independent Director and Roger N. Farah, who is currently serving as Executive Chair of the Board, will continue to serve on the Board.

Also on November 20, 2025, the Company issued a press release announcing the appointment of Mr. Joyner as Chair of the Board. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.**  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(d) Exhibits* 

---

| | |
|:---|:---|
| Exhibit Number | Description |
| 99.1 | [Press Release, dated November 20, 2025.](d172430dex991.htm) |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: November 20, 2025 | CVS HEALTH CORPORATION | CVS HEALTH CORPORATION |
|  | By: | /s/ Kristina V. Fink |
|  | Name: | Kristina V. Fink |
|  | Title: | Senior Vice President, Chief Governance Officer and Corporate Secretary |

---

## Exhibit 99.1

**Exhibit 99.1** 

**PRESS RELEASE** 

WOONSOCKET, RI (November 20, 2025) – CVS Health (NYSE: CVS) today announced that its Board of Directors has elected President and Chief Executive Officer David Joyner as its Chair of the Board, effective January 1, 2026. Following the effective date of this appointment, Michael Mahoney will continue to serve as the Board's Lead Independent Director, and Roger Farah, who is currently serving as Executive Chair of the Board, will continue to serve on the Board.

Joyner was named President and CEO of CVS Health in October 2024, and has led significant operational, financial and cultural improvements in the Company's performance over the past year. In recognition of his leadership, nearly 40 years of experience in the health care industry, and the Company's future growth opportunities, the Board determined Joyner should also serve as Chair of the Board.

"David has sparked a renewed focus and energy for CVS Health in our commitment to be the most trusted health care company in America," said Farah. "The Board believes in the leadership that David and his team have demonstrated. We have determined that now is the right time to have one leader with deep industry experience in the combined Chair and CEO roles, and that this structure will provide the best opportunity to execute on our long-term strategy and create stockholder value. We are bullish on the future of CVS Health in delivering a simpler care experience and better health across our country."

"I am honored to lead our more than 300,000 colleagues who are resolutely driven to simplify health care, one person, one family, and one community at a time," said Joyner. "Our collection of businesses delivers best what people want most: a coordinated and connected approach to health care that is accessible, affordable and available on your terms. We are confident in our future because of the commitment of our colleagues to care for their friends, families and neighbors.

"I am grateful to Roger for his support and guidance as I took on the role of President and CEO. His ongoing counsel is valuable to me, the Board and our leadership team, as we continue to navigate a dynamic environment and drive our strategy."

**About CVS Health** 

CVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of September 30, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including highly rated Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.